Brighton Jones LLC Purchases Shares of 13,344 Illumina, Inc. $ILMN

Brighton Jones LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,344 shares of the life sciences company’s stock, valued at approximately $1,273,000.

Several other hedge funds have also recently modified their holdings of the stock. Diversified Trust Co acquired a new position in Illumina in the 1st quarter worth approximately $355,000. Bourgeon Capital Management LLC grew its stake in shares of Illumina by 76.4% during the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock worth $13,538,000 after purchasing an additional 61,468 shares during the period. GC Wealth Management RIA LLC acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $2,289,000. waypoint wealth counsel purchased a new position in shares of Illumina during the 2nd quarter valued at approximately $321,000. Finally, Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Illumina during the 2nd quarter valued at approximately $344,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ILMN shares. Stephens set a $110.00 target price on Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a research note on Wednesday, October 8th. Citigroup downgraded Illumina from a “hold” rating to a “strong sell” rating and cut their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Daiwa America downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Finally, Barclays lifted their target price on Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research report on Thursday, October 2nd. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $115.25.

Illumina Price Performance

ILMN stock opened at $100.35 on Tuesday. The stock has a market cap of $15.42 billion, a price-to-earnings ratio of 12.70, a PEG ratio of 2.47 and a beta of 1.40. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The business has a 50 day moving average price of $98.17 and a 200 day moving average price of $91.92. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.